A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer

NCT06498518 | Withdrawn Phase 2 DMC

• 1 other identifier: PRIMUS006-2022
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 6

Brief Summary

Trial to investigate if the addition of two novel immunotherapy agents in combination with a chemotherapy agent can reduce the size of the cancer and how long they can delay the growth of the cancer in patients with metastatic pancreatic cancer.

Conditions

Neoplasms Pancreatic

Outcome Measures

Primary Outcomes (1)

• Objective Response Rate

  The proportion of patients achieving an objective response, defined by RECIST 1.1, measured using CT scans for radiological assessment of disease until disease progression

  Measured every 6 weeks by CT scan(most patients will receive 3-4 CT scans over 24 weeks)

Secondary Outcomes (3)

• Progression Free Survival

  At time of progression (estimated to be between 3 and 6 months)

• Safety and Tolerability of Gemcitabine in combination with IMM-101 and Pembrolizumab

  Measured during combination treatment and for up to at least 30 days after the last dose of study therapies. In addition, immune mediated adverse events that occur up to 90 days after the last dose of pembrolizumab

• Overall Survival

  From date of registration until date of death from any cause ( estimated to be between 6-12 months)

Study Arms (1)

IMM-101, Pembrolizumab and Gemcitabine

EXPERIMENTAL

IMM-101: will be administered at a dose of 1mg intra-dermal (ID) between 2 to 7 days prior to first cycle of pembrolizumab (MK-3475)/ gemcitabine then 1mg ID on day 8 of cycle 1, 1mg on day 1 of cycle 2, 1mg on day 8 of cycle 3 then 1mg on day 8 of each cycle thereafter. Pembrolizumab (MK-3475): will be administered at a dose of 200mg by IV infusion every 3 weeks starting from cycle 1, day 1. Gemcitabine: will be administered at a dose of 1000mg/m2 by IV infusion on day 1 and day 8 of every 3 week-cycle starting from cycle 1, day 1. Each cycle is 3 weeks

Drug: IMM-101, Pembrolizumab, Gemcitabine

Interventions

IMM-101, Pembrolizumab, Gemcitabine DRUG

Patients will receive IMM-101, Pembrolizumab, Gemcitabine on a 3 week cycle

IMM-101, Pembrolizumab and Gemcitabine

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients aged \> or = 18 years for age
• Patient has given written informed consent to participate in the trial
• Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma or its variants
• Patient has been enrolled in the Precision-Panc Master Protocol and their tissue has been deemed suitable for Next Generation Sequencing (NGS) analysis.
• No prior systemic anti-cancer therapy for metastatic pancreatic cancer. Patients may have received prior pre-, peri-, or post-operative systemic anti-cancer therapy for operable disease with curative intent provided that the last dose of systemic anti-cancer therapy was completed \> 6 months before the recurrent disease was documented
• ECOG performance status 1, but not sufficiently fit to potentially tolerate treatment with a combination treatment regimen consisting of two or more cytotoxic chemotherapy agents in the opinion of the investigator.
• Measurable disease by RECIST 1.1.
• Estimated life expectancy \> 3 months.
• Adequate haematological and biochemical function.
• Willingness to comply with study procedures including administration of study therapies.
• Females of childbearing potential must have a negative pregnancy test within 72 hours of the first dose of study treatment and agree to use highly effective contraceptive measures during the study and for 6 months after the last administration of the study drug.
• Male patients with partners of childbearing potential must agree to use highly effective contraceptive measures during the study and for 6 months after the last administration of the study drug
• Patients with a history of Hepatitis C Virus (HCV) infection are eligible for the study if HCV viral load is undetectable at screening. Patients who have been treated for HCV infection must have completed curative anti-viral therapy at least 4 weeks before registration to the trial.
• Patients who are hepatitis B positive will be eligible as long as they meet the following criteria:
• Patients who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks and have an undetectable HBV viral load before registration to the trial 14.2. Patients should remain on anti-viral therapy throughout study treatment and follow local guidelines for HBV anti-viral therapy post-completion of study treatment

You may not qualify if:

• Pregnant or breast-feeding women.
• Patients with cardiovascular disease defined as Stage II to IV congestive heart failure (CHF) as determined by the New York Heart Association (NYHA) classification system, or history of myocardial infarction (MI), or cardiac arrhythmia associated with haemodynamic instability, or unstable angina, or cerebral vascular accident, or transient ischemia, if any have occurred within the previous 12 months prior to study treatment.
• Any other serious medical or psychiatric disorder that would be, in the opinion of the investigator, a contra-indication to either the trial procedures or to therapy with gemcitabine, IMM-101 or pembrolizumab.
• Any prior therapy with IMM-101 or an immune checkpoint inhibitor.
• Major surgery within 28 days of starting study treatment and patients must have recovered from any effects of major surgery.
• Patients with a known hypersensitivity to gemcitabine, IMM-101, or pembrolizumab or any of the excipients of the products, including patients who have previously experienced an allergic reaction to any mycobacterial product.
• Current or prior use of immunosuppressive medication within 14 days before the first dose of IMM-101 or pembrolizumab. The following are exceptions to this criterion:
• Intranasal, inhaled, or topical steroids; or local steroid injections (e.g., intra-articular injection) 7.2. Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisolone or equivalent 7.3. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication) and chemotherapy-induced nausea and vomiting
• History of allogenic organ transplant.
• Previous severe or life-threatening skin adverse reaction with other immune-stimulatory anticancer agents.
• Active autoimmune disorders, or prior documented severe autoimmune or inflammatory disorders requiring immunosuppressive treatment in the last 2 years (including inflammatory bowel disease \[e.g., colitis, Crohn's disease\], diverticulitis with the exception of diverticulosis, coeliac disease, irritable bowel syndrome, or other serious gastrointestinal chronic conditions associated with diarrhoea); systemic lupus erythematosus; Wegener syndrome (granulomatosis with polyangiitis), Graves' disease; rheumatoid arthritis, hypophysitis, uveitis or other evidenced autoimmune disorders. The following are exceptions to this criterion:
• Patients with vitiligo or alopecia 10.2. Diabetes mellitus type I or resolved childhood asthma/atopy 10.3. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement 10.4. Any chronic skin condition that does not require systemic therapy 10.5. Patients with coeliac disease controlled by diet alone
• History of (non-infectious) interstitial lung disease or pneumonitis that required steroids or current pneumonitis.
• Patients with an active infection requiring systemic therapy.
• Concurrent active Hepatitis B (defined as HBsAG positive and/or detectable HBV/DNA) or Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA) infection.

Sponsors & Collaborators

• Karen Carty: lead
• NHS Greater Glasgow and Clyde: collaborator
• University of Glasgow: collaborator

Study Sites (6)

University Hospitals Bristol NHS Foundation Trust

Bristol, United Kingdom

Location

University Hospitals Coventry & Warwickshire

Coventry, CV2 2DX, United Kingdom

Location

Beatson West of Scotland Cancer Centre

Glasgow, G12 0YN, United Kingdom

Location

Royal Free London Hospital

London, United Kingdom

Location

Royal Marsden Hospital

London, United Kingdom

Location

The Christie Hospital

Manchester, United Kingdom

Location

MeSH Terms

Conditions

Pancreatic Neoplasms

Interventions

IMM-101; pembrolizumab; Gemcitabine

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Heterocyclic Compounds; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring

Study Officials

• David Chang

  University of Glasgow

  STUDY CHAIR

• Jeff Evans

  University of Glasgow

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Mrs

Study Record Dates

• First Submitted: July 2, 2024
• First Posted: July 12, 2024
• Study Start: June 17, 2024
• Primary Completion: May 23, 2025
• Study Completion: May 23, 2025
• Last Updated: July 11, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, CSR
• Time Frame: After publication of the study
• Access Criteria: Available via request to the Trial Management Group and Co-ordinating Clinical Trials Unit

Locations

GB (6)